Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA106450-01A1
Application #
7129463
Study Section
Subcommittee G - Education (NCI)
Project Start
2005-07-21
Project End
2010-05-31
Budget Start
2005-07-21
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$115,684
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kushner, Brian H; Ostrovnaya, Irina; Cheung, Irene Y et al. (2016) Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget 7:4155-66
Cheung, Nai-Kong V; Cheung, Irene Y; Kramer, Kim et al. (2014) Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 135:2199-205
Dobrenkov, Konstantin; Cheung, Nai-Kong V (2014) GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol 41:589-612
Kushner, Brian H; Modak, Shakeel; Kramer, Kim et al. (2014) Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer 120:2050-9
O'Neill, Alison; Shah, Nilay; Zitomersky, Naamah et al. (2013) Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013:450478
Kushner, Brian H; Modak, Shakeel; Basu, Ellen M et al. (2013) Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer 119:2789-95
Ahn, Eun Hyun; Mercado, Gabriela E; LaƩ, Marick et al. (2013) Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Oncol Rep 30:968-78
Cheung, Nai-Kong V; Cheung, Irene Y; Kushner, Brian H et al. (2012) Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264-70
Tarek, Nidale; Le Luduec, Jean-Benoit; Gallagher, Meighan M et al. (2012) Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 122:3260-70
Lessnick, Stephen L; Ladanyi, Marc (2012) Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 7:145-59

Showing the most recent 10 out of 47 publications